Younger T cells may improve immunotherapy for cancer in kids
New York: Enriching T cells - a type of white blood cell - to attack certain cancerous diseases may prove beneficial to an increasing number of children during immunotherapy, says a study.
Younger T cells, classified as either naive T cells (newly minted cells) or stem central memory T cells (self-renewing, highly proliferative cells) were the most effective in immunotherapy, the study showed.
"Our main finding is that younger T cells are critically important in T cell immunotherapy," said David M. Barrett, paediatric oncologist at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania, US.
Collecting the T cells in the newly-diagnosed patients, even before chemotherapy, or between chemotherapy cycles, instead of after a patient relapses, may be preferable, the researchers explained.
The T cells were found to be more vulnerable to chemotherapy than older cells, showed the findings, published in the journal Science Translational Medicine.
Moreover, adding the signalling proteins interleukin-7 and interleukin-15 to T cell cultures expanded stem central memory cells in samples, the researchers revealed.
The T cell therapy is a form of immunotherapy -- manipulating the body's own immune system.
Specifically, the scientists modify T cells, the workhorses of the body's immune system, to attack B cells (B lymphocytes), other immune cells that become cancerous in specific cancers such as ALL.
The researchers first extracted a patient's own T cells and re-programmed them to hunt down and eliminate B cells after those modified T cells are returned to the patient.
The researchers followed 50 child and adolescent patients in a clinical trial of B-cell cancers at CHOP, of whom 38 had ALL and 12 had non-Hodgkin's lymphoma (NHL).
Younger T cells, classified as either naive T cells (newly minted cells) or stem central memory T cells (self-renewing, highly proliferative cells) were the most effective in immunotherapy, the study showed.
"Our main finding is that younger T cells are critically important in T cell immunotherapy," said David M. Barrett, paediatric oncologist at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania, US.
Collecting the T cells in the newly-diagnosed patients, even before chemotherapy, or between chemotherapy cycles, instead of after a patient relapses, may be preferable, the researchers explained.
The T cells were found to be more vulnerable to chemotherapy than older cells, showed the findings, published in the journal Science Translational Medicine.
Moreover, adding the signalling proteins interleukin-7 and interleukin-15 to T cell cultures expanded stem central memory cells in samples, the researchers revealed.
The T cell therapy is a form of immunotherapy -- manipulating the body's own immune system.
Specifically, the scientists modify T cells, the workhorses of the body's immune system, to attack B cells (B lymphocytes), other immune cells that become cancerous in specific cancers such as ALL.
The researchers first extracted a patient's own T cells and re-programmed them to hunt down and eliminate B cells after those modified T cells are returned to the patient.
The researchers followed 50 child and adolescent patients in a clinical trial of B-cell cancers at CHOP, of whom 38 had ALL and 12 had non-Hodgkin's lymphoma (NHL).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.